PMID- 23551638
OWN - NLM
STAT- MEDLINE
DCOM- 20160627
LR  - 20140616
IS  - 1600-0501 (Electronic)
IS  - 0905-7161 (Linking)
VI  - 25
IP  - 7
DP  - 2014 Jul
TI  - Modification of xenogenic bone substitute materials--effects on the early healing 
      cascade in vitro.
PG  - 852-8
LID - 10.1111/clr.12153 [doi]
AB  - INTRODUCTION: Initial platelet activation with subsequent cytokine release at the 
      defect site plays a crucial role in tissue integration. The aim of this study was 
      to evaluate the influence of topographic and biomimetic collagen modifications of 
      a xenogenic bone substitute material (BSM) on in vitro platelet activation and 
      cytokine release. MATERIAL AND METHODS: Three types of xenogenic BSM were used. 
      Two BSM with different levels of granularity (large granule BSM [XBSM/L], small 
      granule BSM [XBSM/S]) and a BSM with collagen (XBSM/C). All three samples were 
      incubated with platelet concentrate of four healthy volunteers at room 
      temperature for 15 min. For all groups, highly thrombogenic collagen type 1 
      served as a reference and an additional preparation with platelet concentrate 
      only (without XBSM) served as control. Platelet count and cytokine release of 
      VEGF, PDGF, TGF-beta, and IGF into the supernatant were measured. RESULTS: Compared 
      with the control group, XBSM/C showed an increase in platelets consumption (mean 
      41,000 +/- 26,000/ml vs. 471,000 +/- 38,000/ml), cytokine release of VEGF (mean 
      46.8 +/- 7.2 pg/ml vs. 18.8 +/- 2.7 pg/ml), and PDGF (mean 18,350 +/- 795 pg/ml vs. 
      2726 +/- 410 pg/ml) but not IGF (194,728 +/- 51,608 pg/ml vs. 
      1,333,911 +/- 35,314 pg/ml). There was also an increase in cytokine release of 
      TGF-ss in XBSM/C compared with XBSM/S (77,188 +/- 27,413 pg/ml vs. 
      38,648 +/- 13,191 pg/ml), but no such difference when compared with XBSM/L 
      (77,188 +/- 27,413 pg/ml vs. 53,309 +/- 29,430 pg/ml). XBSM/L showed higher platelets 
      consumption (301,000 +/- 45,000 vs. 415,000 +/- 98,000) and a higher cytokine release 
      of PDGF (3511 +/- 247 pg/ml vs. 3165 +/- 78 pg/ml) compared with XBSM/S. There was no 
      distinct difference in the levels of VEGF, TGF-ss, and IGF between XBSM/L and 
      XBSM/S. CONCLUSIONS: Topographic as well as biomimetic modifications of the 
      xenogenic BSM showed an increased platelet activation and cytokine release in 
      vitro. This effect on the intrinsic healing cascade could result in comparable 
      enhanced soft- and hard-tissue regeneration in vivo.
CI  - (c) 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.
FAU - Kammerer, Peer W
AU  - Kammerer PW
AD  - Harvard Medical School, Boston, MA, USA; Department of Oral, Maxillofacial and 
      Plastic Surgery, University Medical Centre Mainz, Mainz, Germany.
FAU - Schiegnitz, Eik
AU  - Schiegnitz E
FAU - Alshihri, Abdulmonem
AU  - Alshihri A
FAU - Draenert, Florian G
AU  - Draenert FG
FAU - Wagner, Wilfried
AU  - Wagner W
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Denmark
TA  - Clin Oral Implants Res
JT  - Clinical oral implants research
JID - 9105713
RN  - 0 (Bio-Oss)
RN  - 0 (Bone Substitutes)
RN  - 0 (Cytokines)
RN  - 0 (IGFBP1 protein, human)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 1)
RN  - 0 (Minerals)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 9007-34-5 (Collagen)
MH  - Biomimetic Materials/chemistry/*pharmacology
MH  - Bone Substitutes/chemistry/*pharmacology
MH  - Collagen/chemistry/*pharmacology
MH  - Cytokines/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - In Vitro Techniques
MH  - Insulin-Like Growth Factor Binding Protein 1/metabolism
MH  - Minerals/chemistry/*pharmacology
MH  - Platelet Activation
MH  - Platelet Count
MH  - Platelet-Derived Growth Factor/metabolism
MH  - Transforming Growth Factor beta/metabolism
MH  - Vascular Endothelial Growth Factor A/metabolism
MH  - Wound Healing/drug effects
OTO - NOTNLM
OT  - biomaterials
OT  - bone regeneration
OT  - bone substitutes
OT  - growth factors
OT  - guided tissue regeneration
OT  - wound healing
EDAT- 2013/04/05 06:00
MHDA- 2016/06/28 06:00
CRDT- 2013/04/05 06:00
PHST- 2013/02/13 00:00 [accepted]
PHST- 2013/04/05 06:00 [entrez]
PHST- 2013/04/05 06:00 [pubmed]
PHST- 2016/06/28 06:00 [medline]
AID - 10.1111/clr.12153 [doi]
PST - ppublish
SO  - Clin Oral Implants Res. 2014 Jul;25(7):852-8. doi: 10.1111/clr.12153. Epub 2013 
      Mar 31.